Industry News
Pharmaceutical Industry News
RFK Jr. Promised Children’s Health Reforms. Here’s How He Did.
A year after the Trump administration laid out its plan to improve the health of American children, we examine where those efforts stand.
Exclusive insights from the…
Exclusive insights from the Patients as Partners Advisory Board on the biggest challenges and opportunities shaping patient engagement, patient advocacy, clinical trial participation, trust, transparency, and patient-focused drug development.
Spying a “golden decade”…
Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar capabilities in the coming years.
While Amgen gave no numerical…
While Amgen gave no numerical results from Imdelltra's latest overall survival win in first-line small cell lung cancer, R&D chief Jay Bradner said data suggest the DLL3 bispecific “will further revolutionize the standard for survival
Shifts in drug pricing and market…
Shifts in drug pricing and market access policies around the world have caused an “earthquake” that will reverberate for years to come, a survey of industry leaders found.
Novo Nordisk has reported a phase…
Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer classified as having obesity after receiving the GLP-1 drug for 68 weeks.
In a rare divergence from its own…
In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new treatment paradigm for molecular-guided
Roche has retained its status as…
Roche has retained its status as the neurology drugmaker that patient groups hold in the highest esteem, once again completing a clean sweep of PatientView’s corporate reputation rankings.
Belgian biopharma UCB is seeking…
Belgian biopharma UCB is seeking to boost awareness of what epilepsy looks like to patients, literally, with a new campaign using art to tell their stories.
Early Data Indicates an A.I.-Generated Drug Could Slow Aging
Artificial intelligence was used to help develop a drug candidate, rentosertib, for a rare lung condition. Its maker says the drug also seems to reduce the biological hallmarks of age.
Ardelyx is running a new ad…
Ardelyx is running a new ad campaign for its irritable bowel syndrome with constipation drug, Ibsrela, across connected TV.
3 Drugs Older People May Be Overusing
Not all older people need these medications, and they can carry increased risks.
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.
Keke Palmer joins Sanofi to share…
Keke Palmer joins Sanofi to share her decision to immunize her son with Beyfortus ahead of the coming respiratory syncytial virus (RSV) season.
The Breztri ad prompts viewers to…
The Breztri ad prompts viewers to "put a LAMA to work" by depicting an AI-generated llama and his barnyard colleagues working a late night in the office.
The Search for New Cures Is Broken
It is too hard for medical researchers to launch clinical trials.
After Jenny Pearson’s daughter…
After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful,” Pearson recalled to Fierce. But a follow-up scan a year later, just days before
Daiichi Sankyo subsidiary American…
Daiichi Sankyo subsidiary American Regent is launching a recall of three lots of generic epinephrine as it becomes one of the latest manufacturers to face headaches over particulate contamination in its drug products.
Move over AbbVie and Johnson &…
Move over AbbVie and Johnson & Johnson, we have a new and surprising leading drug in the pharma ad spending space.
GSK, Roche and Novartis continued…
GSK, Roche and Novartis continued their dealmaking spree with Asian companies. Three midsized Asian biopharmas reached MFN deals with the White House. Akeso and Summit's ivonescimab delivered a head-to-head overall survival win against Keytruda. And